FHA
AVIR icon

First Horizon Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

First Horizon Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,000
Closed -$3.74K – 2396
2023
Q2 		$3.74K Buy
+1,000
New +$3.74K ﹤0.01% 1886

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Horizon Advisors's AVIR Position: Q3 2023 in Review

First Horizon Advisors sold out of Atea Pharmaceuticals (AVIR) in Q3 2023, closing a stake of 1,000 shares — an estimated $3.74K sold.

First Horizon Advisors first reported a position in AVIR in Q2 2023 and held it in 1 quarter. The position peaked at $3.74K in Q2 2023. 119 funds tracked by Wall St. Rank hold AVIR as of Q3 2023.

  • First Horizon Advisors reported no remaining Atea Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • First Horizon Advisors sold 1,000 Atea Pharmaceuticals shares in Q3 2023, an estimated $3.74K.
  • First Horizon Advisors first reported a position in Atea Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • First Horizon Advisors's Atea Pharmaceuticals position peaked at $3.74K in Q2 2023.
  • 119 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2023.

Based on First Horizon Advisors's 13F filing for Q3 2023, filed 27 Oct 2023.